Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 1, 2018European Respiratory JournalOpen Access

RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis

View Full Paper
Ask AI
Bookmark
Share

Authors

TATimothy R. AksamitMayo Clinic in ArizonaASAnthony De SoyzaNewcastle UniversityTBTiemo-Joerg BandelBayer (Germany)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Aksamit et al. (2018) studied this question.

synapsesocial.com/papers/6a00ec7eb124fe581986224chttps://doi.org/10.1183/13993003.02053-2017
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis2018 · 190 citations
  2. 2Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand Thoracic Society of Australia and New Zealand guidelines2015 · 176 citations
  3. 3COPD as a disease of children: hype or hope for better understanding?2009 · 68 citations
  4. 4The RESPIRE trials: Two phase III, randomized, multicentre, placebo-controlled trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis2017 · 44 citations
  5. 5COPD–bronchiectasis overlap syndrome2015 · 209 citations